Undisclosed CNS Pipeline

About Switch Therapeutics

Switch Therapeutics is an emerging, private biotech company developing next-generation RNAi therapies with its innovative CASi platform, which enables cell-selective and conditionally activated gene silencing. The company has raised a $52 million Series A financing round and is building a pipeline focused on CNS disorders. Its leadership combines scientific expertise from Caltech and Harvard with seasoned biotech operational and financial experience, positioning it to tackle complex neurological diseases with a potentially safer and more targeted therapeutic approach.

Therapeutic Areas